title: Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
abstract: BACKGROUND
  Reversal of the residual effect of rocuronium or cisatracurium by neostigmine may be slow and associated with side-effects. This randomized, safety-assessor-blinded study compared the efficacy of sugammadex, a selective relaxant binding agent for reversal of rocuronium-induced neuromuscular block, with that of neostigmine for reversal of cisatracurium-induced neuromuscular block. The safety of sugammadex and neostigmine was also evaluated.
  
  
  METHODS
  Adult surgical patients (ASA class I-III) were randomized to sugammadex 2.0 mg kg(-1) for reversal of block induced by rocuronium 0.6 mg kg(-1), or neostigmine 50 microg kg(-1) for reversal of block induced by cisatracurium 0.15 mg kg(-1). Anaesthesia was induced and maintained using i.v. propofol and remifentanil, fentanyl, or sufentanil. Neuromuscular function was monitored using acceleromyography (TOF-Watch SX). Sugammadex or neostigmine was administered at reappearance of T(2). The primary efficacy variable was time for recovery of the train-of-four (TOF) ratio to 0.9.
  
  
  RESULTS
  Eighty-four patients were randomized, 73 of whom received sugammadex (n=34) or neostigmine (n=39). Time from start of administration of reversal agent to recovery of the TOF ratio to 0.9 was 4.7 times faster with sugammadex than with neostigmine (geometric mean=1.9 vs 9.0 min, P<0.0001). Reversal of block was sustained in all patients. There were no serious adverse effects from either reversal agent and no significant changes in any measure of safety, except for similar elevations in urinary N-acetyl glucosaminidase in both groups.
  
  
  CONCLUSIONS
  Sugammadex 2.0 mg kg(-1) administered at reappearance of T(2) was significantly faster in reversing rocuronium-induced blockade than neostigmine was in reversing cisatracurium-induced block.
authors.affiliation: University Department of Anaesthesia, School of Clinical Sciences, Duncan Building, Daulby Street, Liverpool L69 3GA, UK. lizzy@lizzyflockton.fsnet.co.uk
authors.forename: E A
authors.initials: EA
authors.lastname: Flockton
authors.forename: P
authors.initials: P
authors.lastname: Mastronardi
authors.forename: J M
authors.initials: JM
authors.lastname: Hunter
authors.forename: C
authors.initials: C
authors.lastname: Gomar
authors.forename: R K
authors.initials: RK
authors.lastname: Mirakhur
authors.forename: L
authors.initials: L
authors.lastname: Aguilera
authors.forename: F G
authors.initials: FG
authors.lastname: Giunta
authors.forename: C
authors.initials: C
authors.lastname: Meistelman
authors.forename: M E
authors.initials: ME
authors.lastname: Prins
mesh_terms: D000328:Adult; D000368:Aged; D000732:Androstanols / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D000762:Anesthesia Recovery Period; D000768:Anesthesia, General / Q000379:methods; D001279:Atracurium / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009388:Neostigmine / Q000009:adverse effects / Q000494:pharmacology; D019148:Neuromuscular Blockade / Q000379:methods*; D009469:Neuromuscular Junction / Q000187:drug effects* / Q000502:physiology; D003473:Neuromuscular Nondepolarizing Agents / Q000037:antagonists & inhibitors*; D011446:Prospective Studies; D000077123:Rocuronium; D000077122:Sugammadex; D013997:Time Factors; D047408:gamma-Cyclodextrins / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D000732:Androstanols; D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D001279:Atracurium; D000077122:Sugammadex; D009388:Neostigmine; C101584:cisatracurium; D000077123:Rocuronium